Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
is a novel PDK1 (phosphoinositide-dependent protein kinase 1) activator (Kd = 10
Epub 2011 Sep 22
Valizadeh-Arshad Z
150±302 mm3 compared with 593±328 mm3 for T24 xenograft tumors treated with 5 mg/kg PAI-039 (P<0
Assessment of the protective effect of KN-93 drug in systemic epilepsy disorders induced by pilocarpine in male rat
CPI-444 - CAS# 1202402-40-1 0101 is a novel PDK1 (phosphoinositide-dependentCPI 444, CAS No. 1202402 40 1, is an orally administered antagonist of the adenosine A2A receptor. Upon oral administration, CPI 444 binds to adenosine A2A receptors expressed on the surface of immune cells, including T lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine induced
US$ 1436.00
US$ 10298.00